[go: up one dir, main page]

UY39265A - Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen - Google Patents

Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen

Info

Publication number
UY39265A
UY39265A UY0001039265A UY39265A UY39265A UY 39265 A UY39265 A UY 39265A UY 0001039265 A UY0001039265 A UY 0001039265A UY 39265 A UY39265 A UY 39265A UY 39265 A UY39265 A UY 39265A
Authority
UY
Uruguay
Prior art keywords
syndrome
activators
compounds
pharmaceutical compositions
compositions containing
Prior art date
Application number
UY0001039265A
Other languages
English (en)
Inventor
James Neef
Sung David C Kim
Zaixing Li
Chui Lu
Danuta Lubicka
Hye-Yeon Park
Tejaskumar Pankajbhai Pathak
Amir Masoud Sadaghiani
Xilin Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY39265A publication Critical patent/UY39265A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente divulgación proporciona un compuesto de acuerdo con la fórmula (I) o una sal farmacéuticamente aceptable de este como activadores de CaV1.22 para el tratamiento de esquizofrenia, trastorno bipolar, trastorno depresivo mayor, trastorno debido al uso de sustancias, TDAH, síndrome de Phelan-McDermid, trastornos del espectro autista, esclerosis múltiple, demencia frontotemporal, enfermedad de Alzheimer, síndrome de Brugada, síndrome de QT corto, o síndrome de repolarización precoz.
UY0001039265A 2020-06-15 2021-06-11 Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen UY39265A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/096177 WO2021253180A1 (en) 2020-06-15 2020-06-15 Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators

Publications (1)

Publication Number Publication Date
UY39265A true UY39265A (es) 2022-01-31

Family

ID=76523252

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039265A UY39265A (es) 2020-06-15 2021-06-11 Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen

Country Status (20)

Country Link
US (3) US11919911B2 (es)
EP (1) EP4165047A1 (es)
JP (2) JP7601911B2 (es)
KR (2) KR20250123945A (es)
CN (3) CN120267664A (es)
AR (1) AR122615A1 (es)
AU (1) AU2021293976B2 (es)
BR (1) BR112022025212A2 (es)
CA (1) CA3182354A1 (es)
CL (1) CL2022003525A1 (es)
CO (1) CO2022017502A2 (es)
CR (1) CR20230008A (es)
DO (1) DOP2022000276A (es)
EC (1) ECSP23001748A (es)
IL (1) IL298448A (es)
MX (1) MX2022015866A (es)
PE (1) PE20231079A1 (es)
TW (1) TW202214651A (es)
UY (1) UY39265A (es)
WO (2) WO2021253180A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004596B2 (en) 2014-07-31 2018-06-26 Lensgen, Inc. Accommodating intraocular lens device
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
WO2021255608A1 (en) * 2020-06-16 2021-12-23 Novartis Ag Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
EP4448533A1 (en) * 2021-12-13 2024-10-23 Novartis AG <sup2/>? <sub2/>?v?pyridine-3-carboxylate compounds as ca1.2 activators

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201395A (en) * 1981-07-30 1987-02-20 Bayer Ag Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines
WO1983004023A1 (en) 1982-05-10 1983-11-24 Takeda Chemical Industries, Ltd. Dihydropyridine derivatives
ZA839187B (en) * 1982-12-10 1984-07-25 Ciba Geigy Ag Amide compounds
EP0111455A3 (de) 1982-12-10 1984-07-25 Ciba-Geigy Ag Ungesättigte Lactone
CN1013496B (zh) * 1984-03-23 1991-08-14 拜尔股份公司 1-烷基取代的1，4-二氢吡啶内酯化合物的制备方法
DE3410645A1 (de) * 1984-03-23 1985-09-26 Bayer Ag, 5090 Leverkusen L-alkylsubstituierte 1,4-dihydropyridinlactone, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US4567268A (en) * 1984-04-03 1986-01-28 Merck & Co., Inc. Process for preparation of certain tetrahydrofuro[3,4-b]pyridines
US6518279B2 (en) * 1999-03-04 2003-02-11 Abbott Laboratories Cyclopentanone dihydropyridine compounds useful as potassium channel openers
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2010015037A1 (en) 2008-08-08 2010-02-11 Howard Florey Institute Therapeutic methods and compositions
SG11201806750WA (en) * 2016-02-10 2018-09-27 Janssen Pharmaceutica Nv Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
US10034861B2 (en) * 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
EP3600428A4 (en) 2017-03-23 2020-08-26 Dnarx SYSTEMS AND METHODS FOR THE EXPRESSION OF NUCLEIC ACIDS IN VIVO
AU2018281131B2 (en) * 2017-06-08 2022-01-20 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE9 inhibitors
US20220235011A1 (en) * 2019-05-29 2022-07-28 St Pharm Co., Ltd. Phthalazinone compounds and use thereof
WO2021253180A1 (en) 2020-06-15 2021-12-23 Novartis Ag Methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-4, 5, 6, 7-tetrahydro-1h-cyclopenta [b] pyridine-3-carboxylate and methyl (r) -2- (fluoromethyl) -5-oxo-4-phenyl-1, 4, 5, 7-tetrahydrofuro [3, 4-b] pyridine-3-carboxylate as cav1.2 activators
WO2021255608A1 (en) 2020-06-16 2021-12-23 Novartis Ag Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators

Also Published As

Publication number Publication date
US20250304594A1 (en) 2025-10-02
KR102845488B1 (ko) 2025-08-13
JP2023530917A (ja) 2023-07-20
AU2021293976A1 (en) 2022-11-24
CA3182354A1 (en) 2021-12-23
ECSP23001748A (es) 2023-03-31
US20250002499A1 (en) 2025-01-02
DOP2022000276A (es) 2023-01-15
IL298448A (en) 2023-01-01
TW202214651A (zh) 2022-04-16
CN115836076A (zh) 2023-03-21
JP2025032216A (ja) 2025-03-11
MX2022015866A (es) 2023-01-24
US20210395261A1 (en) 2021-12-23
AU2021293976B2 (en) 2023-12-14
US12365690B2 (en) 2025-07-22
CN115836076B (zh) 2025-04-25
WO2021253180A1 (en) 2021-12-23
CR20230008A (es) 2023-01-25
JP7601911B2 (ja) 2024-12-17
BR112022025212A2 (pt) 2023-01-03
CL2022003525A1 (es) 2023-08-11
AR122615A1 (es) 2022-09-21
PE20231079A1 (es) 2023-07-17
KR20230022982A (ko) 2023-02-16
US11919911B2 (en) 2024-03-05
KR20250123945A (ko) 2025-08-18
CN120267665A (zh) 2025-07-08
WO2021255607A1 (en) 2021-12-23
CN120267664A (zh) 2025-07-08
EP4165047A1 (en) 2023-04-19
CO2022017502A2 (es) 2022-12-20

Similar Documents

Publication Publication Date Title
UY39265A (es) Compuestos como activadores de cav1.2 y composiciones farmacéuticas que los contienen
CL2022001739A1 (es) Compuestos tricíclicos sustituidos
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
CR20250187A (es) Compuestos tricíclicos y sus usos
AR122593A1 (es) Compuestos de dihidroquinolinsulfonamida de ciclopropilo
CO2022002804A2 (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos
AR128931A1 (es) Inhibidores del factor b del complemento y usos de los mismos
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR127254A1 (es) Ciertas octahidrofuro[3,4-b]pirazinas como moduladores del receptor de glp-1
AR076645A1 (es) Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales.
MX2019014368A (es) Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica.
AR127470A1 (es) Inhibidores de lrrk2
AR126077A1 (es) Compuestos de pirrolil-sulfonamida
AR127064A1 (es) Prodroga de derivados de pirrolidona como activador de glucoquinasa
AR131263A1 (es) Compuestos de pirrolil-sulfonamida fusionados
AR120174A1 (es) Inhibidores del factor d del complemento para administración oral
AR125358A1 (es) Inhibidores heteroaromáticos bicíclicos de la peptidasa 5 relacionada con la calicreína (klk5)
AR127031A1 (es) Derivados de 3-fenoxiazetidin-1-il-heteroaril pirrolidina y el uso de estos como medicamento
AR127255A1 (es) NUEVOS DERIVADOS DE BENZODIAZEPINA COMO GABAA g1 PAM
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
UY39267A (es) Compuestos de metil 2-metil-5-oxo-1,4,5,7-tetrahidrofuro[3,4-b]piridina-3-carboxilato como activador
AR120170A1 (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
AR070949A1 (es) Compuestos derivados de sulfamato de uso medico, medicamentos y composiciones farmaceuticas que los comprenden, procedimientos para preparar estos compuestos y su uso
AR128100A1 (es) Compuestos para el tratamiento de la pérdida del cabello